Medtronic plc research snapshot
MDT AI stock analysis currently reads Medtronic plc as a durable global medical technology business whose FY2026 revenue growth improved, but whose stock still needs disciplined execution after the MiniMed IPO, tariff pressure, tax matters, and long-cycle device regulation. At the July 8, 2026 data cutoff, MDT traded near $83.83, had a calculated market capitalization near $107.32 billion, and produced FY2026 revenue of $36.364 billion with $5.426 billion of free cash flow. This MDT AI stock analysis uses scenario ranges, not a guaranteed price prediction, and it is informational research rather than investment advice.
Current price
$83.83
Market cap
$107.32 billion calculated, $107.31 billion reported reference
AI score
76 / 100
Rating
Large-cap medtech compounder with improving growth and moderate valuation discipline required
Trend status
Constructive technical trend: price is above the 50-day and 200-day moving averages in the Investing.com daily snapshot
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Medtronic sells device-based therapies across cardiovascular, neuroscience, medical surgical, and diabetes categories, serving hospitals, physicians, and patients with recurring procedure demand. | High |
| Moat | The moat comes from clinical evidence, regulatory approvals, physician training, installed workflows, manufacturing quality, global distribution scale, and a deep product portfolio. | High |
| Management | Management delivered the strongest annual revenue growth in a decade in FY2026 and completed the MiniMed IPO, but the next test is converting pipeline breadth into margin and per-share value. | Medium-high |
| Financial trend | FY2026 net sales rose 8.4% to $36.364 billion, GAAP EPS rose to $3.73, cash from operations reached $7.330 billion, and free cash flow reached $5.426 billion. | High |
| Valuation | At $83.83, MDT trades near 22.5x GAAP EPS, 14.1x the FY2027 adjusted EPS guidance midpoint, 19.8x free cash flow per share, and a 3.44% dividend yield. | High for math, medium for forward value |
| Technical trend | The chart is constructive but not risk-free. Investing.com showed MDT above its 50-day and 200-day moving averages with RSI near 57.8, while price remained below the 52-week high. | Medium |
| Risk level | Risk is medium because procedure demand, product approvals, recalls, reimbursement, tariffs, tax disputes, debt, and MiniMed separation outcomes can affect earnings quality. | Medium-high |
| AI confidence | The data set is strong, but much of the stock debate depends on forward organic growth, margin recovery, pipeline timing, and market multiples rather than static historical facts. | High data confidence |
| Investment certainty | MDT has the shape of a quality medtech holding, but the buy case needs evidence that FY2026 growth is durable and that FY2027 EPS guidance is achievable without sacrificing investment. | Medium |
MDT AI stock forecast
The MDT AI stock forecast uses scenario math around the $83.83 price reference, FY2027 adjusted EPS guidance midpoint near $5.95, and a three-year earnings multiple framework. The audited model produced a bearish area near $78, a base area near $106, and a bullish area near $135 before dividends and future capital allocation effects.
$125 to $135
More likely if Cardiovascular growth stays strong, Affera and other ablation platforms keep momentum, Hugo and other pipeline assets scale, tariffs are managed, MiniMed value is clarified, and investors assign an upper-teens earnings multiple.
$100 to $110
More likely if organic revenue grows near the FY2027 guide, adjusted EPS compounds around mid-single to high-single digits, free cash flow conversion remains solid, and MDT holds a mid-teens earnings multiple.
$75 to $80
More likely if revenue growth slows, product launches disappoint, reimbursement or regulatory issues appear, tax or litigation reserves expand, or the market prices MDT closer to a low-teens earnings multiple.
MDT AI technical analysis
MDT AI technical analysis is constructive as of the July 8, 2026 cutoff. Investing.com showed MDT at $83.83, a day range of $83.73 to $85.99, a 52-week range of $73.31 to $106.33, RSI near 57.842, a 50-day moving average near $81.43, and a 200-day moving average near $79.66. The setup supports a recovery trend, but resistance remains above the recent pivot zone.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $83.83 | Investing.com listed MDT at $83.83 around the July 8, 2026 data cutoff. |
| Immediate support | $83.63 to $83.82 | Investing.com classic pivot support levels clustered in this area. A break below it would weaken the very short-term setup. |
| Trend support | $81.43 and $79.66 | These are the cited 50-day and 200-day moving averages. Holding above both supports the current recovery read. |
| Deeper support | $73.31 | The cited 52-week low is the major downside reference if the recovery fails. |
| Near resistance | $84.16 to $85.99 | The lower bound is the classic R1 pivot and the upper bound is the cited recent day high. |
| Longer resistance | $97.77 to $106.33 | The lower area is near the StockAnalysis average price target and the upper area is the cited 52-week high. |
| Momentum | RSI near 57.842, MACD positive | The daily technical snapshot classified indicators as constructive without showing an extreme overbought reading. |
| Volume and volatility | Medium monitoring priority | Earnings on August 25, 2026, FY2027 guidance updates, product approvals, and MiniMed separation details can change the setup. |
| Invalidation | Close below $79.50, then $73.31 | A close below the 200-day area would weaken the trend-following case. A move below the 52-week low would invalidate the recovery framework. |
MDT AI trading strategy
The MDT AI trading strategy below is a rules-based research framework, not personal advice. It connects Medtronic fundamentals, FY2027 guidance, dividend and cash flow quality, and technical confirmation with predefined invalidation levels.
Watch for MDT to hold above the $81 to $80 moving-average zone and push through the $84 to $86 resistance area. Confirmation should include stable FY2027 EPS guidance, strong Cardiovascular growth, and no adverse update on MiniMed, tax, or regulatory matters.
A failed breakout followed by a close below the 200-day moving average area should reduce setup confidence because it would show the recovery lacks institutional follow-through.
If MDT pulls back toward $80 without a guidance cut, compare the selloff with cash flow, dividend coverage, procedure-volume commentary, Cardiovascular growth, Diabetes separation news, and medtech peer performance.
Do not treat weakness as benign if it is tied to lower FY2027 guidance, product safety issues, reimbursement pressure, or a material increase in tax or litigation exposure.
Track organic revenue growth, adjusted EPS, free cash flow, operating margin, Cardiovascular growth, neuroscience growth, medical surgical margin, R&D pipeline progress, share repurchases, debt reduction, and MiniMed disclosures.
Position sizing should reflect device regulation, product recall risk, long sales cycles, payer pressure, tariffs, tax reserves, and the fact that dividend stability does not remove equity drawdown risk.
Investment research summary
Medtronic is paid because hospitals and physicians need reliable devices and therapies that treat heart disease, neurological disorders, surgical conditions, and diabetes care needs. The customer value is clinical reliability, procedure support, and patient outcomes.
Medtronic has brand trust among clinicians, high switching friction inside procedure workflows, regulatory approvals, manufacturing scale, clinical data, global sales reach, and technology platforms in cardiac rhythm, ablation, spine, surgical tools, and diabetes.
The thesis fails if growth platforms do not scale, product quality slips, regulators delay approvals, payers pressure device economics, tax liabilities expand, MiniMed separation creates distraction, or debt limits capital allocation flexibility.
Management under CEO Geoff Martha has pushed portfolio focus, growth-driver investment, MiniMed separation, dividends, and buybacks. The key capital allocation question is whether R&D, acquisitions, dividends, debt, and repurchases create per-share value together.
Aging populations, chronic disease, minimally invasive procedures, cardiac ablation, robotic and digital surgery, remote monitoring, and diabetes technology support long-term medtech demand. Regulation, reimbursement, and hospital budgets are the counterweights.
At $83.83, MDT is not priced like a high-growth medtech stock, but the margin of safety depends on FY2027 adjusted EPS near $5.90 to $6.00, organic growth near guidance, and free cash flow remaining strong enough to fund dividends and reinvestment.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $83.83 as of July 8, 2026 | Investing.com MDT quote snapshot | July 8, 2026 |
| Shares outstanding | 1,280,177,293 ordinary shares outstanding as of April 24, 2026 | Medtronic FY2026 Form 10-K | July 8, 2026 |
| Market capitalization verification | $107.32 billion calculated from $83.83 x 1,280,177,293 shares, compared with $107.31 billion reported reference | Pineify financial_rigor.py and Investing.com market cap reference | July 8, 2026 |
| FY2026 net sales | $36.364 billion, up 8.4% as reported | Medtronic FY2026 Form 10-K and FY2026 earnings release | July 8, 2026 |
| FY2026 net income attributable to Medtronic | $4.801 billion, GAAP diluted EPS $3.73 | Medtronic FY2026 Form 10-K | July 8, 2026 |
| FY2026 free cash flow | $5.426 billion from $7.330 billion operating cash flow | Medtronic FY2026 earnings release | July 8, 2026 |
| Cash and current investments | $9.220 billion, including $1.949 billion cash and $7.271 billion investments | Medtronic FY2026 Form 10-K | July 8, 2026 |
| Debt | $1.788 billion current debt obligations and $26.173 billion long-term debt | Medtronic FY2026 Form 10-K | July 8, 2026 |
| FY2026 segment structure | Cardiovascular, Neuroscience, Medical Surgical, and consolidated MiniMed diabetes business | Medtronic FY2026 Form 10-K | July 8, 2026 |
| Q4 FY2026 segment revenue | Cardiovascular $3.797 billion, Neuroscience $2.751 billion, Medical Surgical $2.388 billion, Diabetes $837 million | Medtronic FY2026 earnings release | July 8, 2026 |
| Technical snapshot | RSI 57.842, 50-day moving average $81.43, 200-day moving average $79.66 | Investing.com MDT technical analysis | July 8, 2026 |
| FY2027 guidance | Organic revenue growth guidance 6.75% to 7.25% and adjusted EPS guidance $5.90 to $6.00 | Medtronic FY2026 earnings release | July 8, 2026 |
This MDT AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and may be wrong if Medtronic guidance, product approvals, regulatory outcomes, market multiples, interest rates, or investor sentiment change.
